BioSpace News Archive

COVID-19 cases are soaring in China, Hong Kong, the U.K. and parts of Europe. A recent Demy-Colton Virtual Salon explored what we can expect in the near future.

The FDA’s Peripheral and Central Nervous System Drugs Advisory Committee will face its first big test since Aduhelm as it weighs the merits of Amylyx’s AMX0035 for ALS on Wednesday, March 30.

Innovent Biologics, Inc. and Eli Lilly and Company announced that in light of both parties’ shared commitment to continue bringing innovative medicines to benefit Chinese patients and to leverage the strengths of each party in a win-win manner, parties will now expand the strategic partnership through:

InnoCare Pharma announced that the company has received Investigational New Drug approval of clinical trial from the NMPA for its TYK2 JH2 allosteric inhibitor ICP-488, which is the Company’s third innovative drug for the treatment of autoimmune diseases to enter the clinical stage.

Ascletis Pharma Inc. announces that the latest preclinical research results of the company’s two novel anti-cancer drug candidates, ASC61, an oral PD-L1 inhibitor and ASC60, an oral fatty acid synthase inhibitor have been selected for presentations at the American Association for Cancer Research Annual Meeting 2022, and the abstracts have already been published on AACR’s official website.

The multi-center, open-label, Phase 1b/2 study to evaluate the tolerability, efficacy, safety and PK/PD of CAN106 administered intravenously to complement inhibitor treatment-naïve PNH patients, is under the direction of principal investigator, Dr. Bing Han, Director of Hematology, at the Peking Union Medical College Hospital.